Updated Data From the LEAHRN Study in High-Risk Neuroblastoma


Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.

Related Videos
Expert on ovarian cancer
Expert on ovarian cancer
Related Content